Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Pfizer's PD-1 prospect beats age-old incumbent in phase 3 bladder cancer trial Seagen took the HER2-directed ADC into a phase 3 trial in people with previously untreated urothelial cancer in 2023.

Astellas and Seagen's Padcev is on course to move further up the treatment pathway in bladder cancer, thanks to a positive readout in the EV-103 clinical trial. The latest results come from cohort ...

This was primarily driven by legacy Seagen, Vyndaqel family, Eliquis, Nurtec ODT/Vydura, and Xtandi, partially offset by lower revenues for Abrysvo, Xeljanz and Oncology biosimilars. Read Next ...

A two-decade bet on a biotechnology company turned into a roughly $8 billion windfall for investors in a New York hedge fund earlier this year. Baker Bros. Advisors, a hedge-fund firm run by ...

Quarterly sales of cancer therapy Padcev, acquired with Seagen, came in at $444 million, compared with estimates of $440 million. The company implemented cost-cutting measures and expects to save ...

The antibody-drug conjugates or ADCs, Adcetris, Padcev, Tukysa and Tivdak, added to Pfizer’s portfolio with the Seagen acquisition in December 2023, boosted Pfizer’s oncology sales in the ...

Recently, Pfizer has concentrated on expanding its oncology segment, enhanced by the March 2023 acquisition of Seagen. This focus on oncology highlights the importance of research and development ...

We made great progress with commercial execution and achieved growth across our product portfolio for full-year 2024, including $3.4 billion in revenue from our legacy Seagen portfolio ...

Offshore Biotechnologies and partner SeaGen Aquaculture have cultivated over 100 species of marine sponges to support new ...